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Abstract
Endothelial-to-mesenchymal transition (EndMT) occurs during development and underlies the 
pathophysiology of multiple diseases. In tumors, unscheduled EndMT generates cancer-associated 
myofibroblasts that fuel inflammation and fibrosis, and may contribute to vascular dysfunction 
that promotes tumor progression. We report that freshly isolated subpopulations of tumor-specific 
endothelial cells (TEC) from a spontaneous mammary tumor model undergo distinct forms of 
EndMT in response to TGFβ stimulation. Whereas some TEC strikingly up-regulate alpha smooth 
muscle actin (SMA), a principal marker of EndMT and activated myofibroblasts, counterpart 
normal mammary gland endothelial cells (NEC) showed little change in SMA expression after 
TGFβ treatment. Compared with NEC, SMA+ TEC were 40 % less motile in wound healing 
assays and formed more stable vascular-like networks in vitro when challenged with TGFβ. 
Lineage tracing using ZsGreenCdh5-Cre reporter mice confirmed that only a fraction of vessels in 
breast tumors contain SMA+ TEC, suggesting that not all endothelial cells (EC) respond 
identically to TGFβ in vivo. Indeed, examination of 84 TGFβ-regulated target genes revealed 
entirely different genetic signatures in TGFβ-stimulated NEC and TEC cultures. Finally, we found 
that basic FGF (bFGF) exerts potent inhibitory effects on many TGFβ-regulated genes but 
operates in tandem with TGFβ to up-regulate others. EC challenged with TGFβ secrete bFGF 
which blocks SMA expression in secondary cultures suggesting a cell-autonomous or lateral-
inhibitory mechanism for impeding mesenchymal differentiation. Together, our results suggest 
that TGFβ-driven EndMT produces a spectrum of EC phenotypes with different functions that 
could underlie the plasticity and heterogeneity of the tumor vasculature.
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Introduction
Endothelial-to-mesenchymal transition (EndMT) is defined as the loss of endothelial-
specific factors and gain of mesenchymal features that accompany the morphogenesis of 
specific tissues, especially those of the heart (1). EndMT also occurs in various pathological 
conditions including cerebral cavernous malformations, cardiac and kidney fibrosis, vein 
stenosis, and cancer (2–7). In these diseased states, aberrantly regulated EndMT results in 
unscheduled conversion of endothelial cells (EC) into diverse mesenchymal-lineage cell 
types, especially myofibroblasts, that may dissociate from the vessel wall and can be found 
throughout the affected tissue (8–14). EndMT coincides with genome-wide reprogramming 
that allows EC to exist in a variety of phenotypic states but may also cause vascular 
dysfunction that contributes to disease progression (9,15,16).
The concept that EC may “drift” towards mesenchymal-like cell types was shown many 
years ago in transforming growth factor beta- (TGFβ) treated EC cultures (17). TGFβ, and 
other members of the TGFβ superfamily, impart plasticity to EC by activation of specific 
transcription factors (e.g. Snail, Slug, and Twist) that interact with chromatin modifiers to 
create genome-wide epigenetic reconfigurations (15,18). Whether acquisition of the 
mesenchymal program in EC is a partial and transient or stable and transmittable change in 
cellular specification is not clear. The context-dependency of TGFβ, combined with its cell-
type specific activity, has made it challenging to understand how EC react to sustained 
TGFβ signaling, particularly in complex tissues such as tumors (19,20). In addition, EC 
responses to TGFβ may proceed differently in different types of EC owing to heterogeneous 
forms of mesenchymal differentiation throughout the vasculature that is tumor-type and/or 
tumor-stage dependent.
Recently, we isolated normal mammary gland EC (NEC) and mammary tumor EC (TEC) 
from a transgenic tumor model (21). We were surprised to find a wide range of 
mesenchymal-like genetic signatures among these different types of EC challenged with 
TGFβ in vitro. Furthermore, whereas some TGFβ-stimulated mesenchymal genes (e.g. 
smooth muscle actin alpha, SMA) were blocked by addition of basic fibroblast growth factor 
(bFGF), expression of other mesenchymal genes was augmented by the combination. These 
results require a refined assessment for how EndMT is defined across different vascular 
beds. In principle, EndMT may be characterized by a spectrum of intermediate and 
reversible mesenchymal-cell phenotypes, especially in pathological tissues. Moreover, EC 
resist specific conversion to SMA+ myofibroblast-like cells when challenged with TGFβ 
through secretion of bFGF; thus, EC maintain their own fate and differentiation by a self-
regulatory mechanism that counteracts TGFβ activity.
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EC isolation, cell culture and media
Mammary NEC and TEC were isolated from C3-TAg (FVB/N C31-TAg) mice and FVB 
wild-type mice, respectively (21). We previously isolated prostate TEC from TRAMP mice 
(8), and K-Ras lung TEC were isolated from K-RasG12D mouse lung tumors (22). 
Fluorescently labeled acetylated low-density lipoprotein (DiI-Ac-LDL) (Biomedical 
Technologies) were incubated with lung TEC clones to examine cell purity under a 
fluorescent microscope (23). EC clones were maintained in 1 g/L D-glucose DMEM (LG-
DMEM, Gibco) supplemented with 10 % fetal bovine serum (FBS), 10 % Nu-Serum IV 
(BD), 5 ng/mL bFGF (Peprotech), 10 ng/mL vascular endothelial growth factor A (VEGF) 
(Peprotech), and 20 USP units/mL heparin (Sigma). Mouse mesenchymal stem cells (MSC) 
were purchased from Gibco and were maintained in DMEM/F-12 (Gibco) with 10 % MSC-
qualified FBS (Gibco). All media were supplemented with antibiotic–antimycotic (Gibco).
Unless otherwise stated, 5 ng/mL bFGF and/or 10 ng/mL TGFβ2 in 20 % FBS or 1 % FBS 
LG-DMEM was used to treat cells for 48 hours prior to protein or RNA extraction. BMP-2 
(Peprotech), BMP-6 (Peprotech), and BMP-7 (Peprotech) were used at 100 ng/mL. Small-
molecule inhibitors were added to the media for one hour before TGFβ2 treatment. Reagents 
used: TGFβ2R inhibitor (SB431542, Sigma), phosphoinositide 3-kinase (PI3K) inhibitor 
LY294002 (Sigma), Akt inhibitor VIII (EMD Millipore), Smad3 inhibitor SIS3 
(Calbiochem), mammalian target of rapamycin (mTOR) inhibitor rapamycin (Sigma), MEK 
(MAPK/ERK kinase) 1/2 inhibitor U0126 (Calbiochem), bFGF neutralizing antibody 
(Millipore, 05-117), and FGF receptor (FGFR) kinase inhibitor (Calbiochem).
Real-time quantitative PCR (qPCR)
Total RNA isolation was completed using an RNeasy Mini Kit (Qiagen) according to the 
manufacturer’s instructions, and cDNA synthesis was carried out using an iScript cDNA 
Synthesis Kit (Bio-Rad). qPCR was run in triplicate in 10 μL/reaction with 2X Maxima 
SYBR Green (ThermoFisher) on an Applied Biosystems Step One Plus analyzer. The 
threshold cycle (Ct) values were determined by Step One Software 2.2.2 by Applied 
Biosystems. Ct values of Gapdh gene expression were used as an endogenous control. The 
relative expression of each gene was quantified using the formula: 2e(Ct of Gapdh – Ct of gene X) 
= fold increase of reference gene expression. Primer sequences are available upon request. 
Heat maps were generated using Gene-E (http://www.broadinstitute.org/cancer/software/
GENE-E/.)
Western blots
Cells were lysed in RIPA buffer complemented with phosphatase and protease inhibitor 
cocktails (Sigma) for protein extraction. Protein concentrations were determined by 
Bradford assays, and ~ 30 μg per sample was used for Western blotting. For non-
phosphorylated protein detection, membranes were blocked and antibodies were added in 5 
% milk tris-buffered saline with 0.1 % Tween 20 (TBST), and for phosphorylated protein 
detection, 5 % bovine serum albumin (BSA) TBST was used. Membranes were incubated 
with primary antibodies at 4 °C overnight and then with secondary antibody at room 
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temperature for one hour. Primary antibodies: 1:1000 mouse anti-SMA (Sigma, A5228), 
1:1000 rabbit anti-phospho-Ser 465/467 SMAD2 (pSMAD2) (Cell Signaling, 3108), 1:1000 
rabbit anti-phospho-Ser 423/425 SMAD3 (pSMAD3) (Millipore, 0713-89), 1:1000 rabbit 
anti-SMAD2 (Cell Signaling, 5339), 1:1000 rabbit anti-SMAD2/3 (Cell Signaling, 8685), 
1:1000 rabbit anti-fibronectin (Abcam, ab2413), 1:1000 rabbit anti-bFGF (Sigma), 1:1000 
rabbit anti-phospho-Thr 202/204 ERK (pERK) 1/2 (Cell Signaling, 4370), 1:2000 rabbit 
anti-ERK1/2 (Cell Signaling, 9102), 1:1000 rabbit anti-VEGF receptor 2 (VEGFR2) (Cell 
Signaling, 55B11), and 1:2500 rabbit anti-GAPDH (Cell Signaling, 5174). Secondary HRP-
conjugated antibodies: 1:10,000 horse anti-mouse and 1:10,000 goat anti-rabbit antibodies 
(Vector Laboratories).
Wound closure scratch assay and live imaging
Cells were plated at 1.0 × 105 cells/well in 6-well plates. Twenty-four hours later, the 
monolayer was gently scratched with a 200 μL pipette tip across the center of the well. An 
Olympus IX70 Inverted Live Cell System was used for time-lapse imaging of the cells at a 
minimum of four locations/well at 20-minute intervals until the scratch wound was 
completely closed. The images were acquired with the Volocity 6.2 software package 
(Perkin Elmer) and analyzed using TScratch software (available at: http://www.cse-
lab.ethz.ch) according to the developers’ instructions. (24). The open areas on the images 
were quantified with the software’s automated image analysis and expressed as relative area 
closure with an arbitrary area unit assigned by the software. Phase contrast images were 
captured with a Hamamatsu ORCAR2 camera.
Matrigel tube formation assay
Growth factor-reduced Matrigel (Corning, 356230) was first plated into 96-well plates and 
allowed to set for 30 minutes at 37°C. Cells were pre-incubated in 10 % FBS medium with 
or without TGFβ2 for 16 hours before being detached and plated in 10 % FBS medium with 
or without TGFβ2 in Matrigel-containing wells in triplicate at a density of 1.0 × 104 cells/
well. Phase contrast images (4×) were taken on an Evos® XL Core Cell Imaging System 
(Life Technologies) at ~ seven hours. Images were processed with ImageJ using the “find 
edges” feature to enhance the contrast. Quantification was done by counting vessel-like 
cords that were formed by at least two non-adjacent cells. A 3 × 3 grid was superimposed on 
each image, and at least four random squares were counted per image to obtain an average 
number of tubes per image.
Flow cytometry
Flow cytometry was performed using a BD Accuri® C6 Flow Cytometer as previously 
described with data analyzed post-hoc using FloJo (version X) (21). Antibodies: PE rat anti-
mouse CD31 (BD Pharmingen, 553373), PE rat anti-mouse CDH5 (VE-cadherin) (BD 
Pharmingen, 562243), and rat anti-mouse IgG (BD Pharmingen, 55393) at a ratio of 1.5 μL 
antibody to 100 μL of cell suspension.
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Tumor studies in mice
C3-TAg mice were provided by the Mouse Phase 1 Unit from the Lineberger 
Comprehensive Cancer Center at UNC Chapel Hill. Tumors were harvested when mice were 
approximately five months of age. ZsGreenCdh5-Cre mice were generated by crossing R26 
ZsGreen mice (Jackson Laboratory, 007906) and Cdh5-Cre mice (Jackson Laboratory, 
006137). E0771 murine mammary tumor cells (CH3 BioSystems, 940001) or PyVMT tumor 
cells isolated from the PyVMT mice were suspended in Matrigel (Corning, 356234) at a 
density of 1.0 × 107 cells/mL, and 100 μL of cell suspension was orthotopically injected into 
the mammary fat pats of seven week-old female ZsGreenCdh5-Cre mice (25). Tumors were 
harvested when they reached 1 cm3 in size, and normal mammary glands from age-matched 
littermates were harvested at the same time. Lung tumors were obtained from K-RasG12D 
mice (22). Tissues were fixed in 4 % paraformaldehyde and cryoprotected in 30 % sucrose-
phosphate buffered saline (PBS) before OCT embedment and cryosection. All mouse 
experiments were carried out under approval of the Institutional Animal Care and Use 
Committee at UNC-Chapel Hill.
Immunofluorescence (IF)
IF methods were described previously (8). Antibodies used were: 1:100 rat anti-mouse 
CD31 antibody (BD, 550274), 1:200 Alexa Fluor® 488 goat anti-rat antibody (Invitrogen, 
A11006), and 1:500 monoclonal mouse anti-α-smooth muscle actin (SMA) Cy3 antibody 
(Sigma, C6198). Slides were mounted with Vectashield Hardset Mounting Medium with 
DAPI (Vector Labs) and imaged on a Zeiss CLSM 710 or 700 Spectral Confocal Laser 
Scanning Microscope.
Three-dimensional confocal microscopy
Sections were stained as described above, and imaged on a Zeiss CLSM 710 Spectral 
Confocal Laser Scanning Microscope using cubic voxels to capture the z-dimension. Three-
dimensional projections, orthogonal slices, and the supplementary movie (Movie S1) were 
generated using ImageJ (http://imagej.nih.gov/ij/).
TGFβ pathway qPCR array
The array was carried out in duplicate using the Mouse TGFβ Signaling Targets RT2 
Profiler™ PCR Array (SA Biosciences, PAMM-235Z) according to the manufacturers’ 
instructions. Cells were plated and exposed to TGFβ2 and/or bFGF for 48 hours. Total RNA 
was purified with an RNeasy Mini Kit (Qiagen) and cDNA synthesis was performed with an 
iScript cDNA Synthesis Kit (Bio-Rad). ABI 7900HT Quantitative PCR System was used for 
the qPCR array and the data were analyzed with SA Biosciences’ RT2 Profiler™ PCR Array 
Data Analysis Online Software.
Conditioned-media (CM) treatment of TEC-H8
CM collected from TEC-H8 treated with or without TGFβ2 (10 ng/mL) for 48 hours were 
concentrated using Amicon Ultra-15 Centrifugal Filter Unit (Millipore) or Pierce Protein 
Concentrators (Thermo Scientific). For Western analysis of bFGF, 25 μL of the concentrated 
CM was used, and the remaining concentrated CM were then divided equally to treat a new 
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batch of TEC-H8 for 48 hours in the presence or absence of freshly added TGFβ2. Cell 
lysates were collected for Western and qPCR analyses.
Statistics
All values are expressed as ± standard error of mean (SEM). Results were analyzed by a 
student’s t-test or ANOVA using GraphPad Prism 5 software. P values less than 0.05 were 
considered significant.
Results and discussion
Isolation of TEC with an intermediate EndMT phenotype
We recently isolated multiple NEC and TEC clones from wild-type mice and spontaneous 
mammary tumors in C3-TAg mice using a high-fidelity cloning method producing pure EC 
populations uniformly positive for CD31 and CDH5 (Fig. 1A and 1B) (21). Surprisingly, a 
number of TEC clones showed elevated basal mRNA expression of the EndMT and 
myofibroblast differentiation marker, SMA (Acta2) (Fig. 1C). On the other hand, expression 
of endothelial markers Cd31 and Vegfr-2 were variable among all NEC and TEC clones and 
did not correlate with the levels of Acta2 mRNA (Fig. 1C). When challenged with TGFβ2, 
TEC-H8 (a clone with high basal SMA expression) up-regulated SMA protein expression, 
whereas an NEC clone (B12) and TEC-A2 (a SMA-low TEC clone) were relatively 
unresponsive (Fig. 2A). TEC-H8 were responsive to all three TGFβ isoforms and similar 
results were obtained using an additional mammary TEC clone with high SMA mRNA 
(TEC-D8) and mesenchymal-like prostate TEC previously described by us (Fig. 2B and 2C) 
(8). As non-EC (e.g. SMA+ fibroblast) contamination can occur during EC isolation, we 
performed staining with SMA and CD31 to exclude this possibility. All individual cells in 
the TEC clone examined expressed CD31, and confocal images clearly revealed co-
localization of SMA+ stress fibers and CD31 in the same cells post-TGFβ2 treatment (Fig. 
2D). SMA+ EC have been observed in the luminal surface of healthy thoracic aorta, but their 
density is markedly increased in atheromatous aorta (26). The appearance of SMA+ EC 
correlates with a pro-inflammatory state, such as in tumors or fibrosis, where TGFβ is also 
highly up-regulated (27,28). It is possible that the tumor microenvironment promotes the 
conversion of SMA− EC into SMA+ EC, or favors the enrichment of rare but pre-existing 
SMA+ EC located throughout the mammary gland vasculature.
To test whether there were any functional differences between SMA-high TEC and NEC, 
we carried out a time-lapse wound healing migration assay using TEC-H8 and NEC-B12 
clones. NEC-B12 challenged with TGFβ2 showed little difference in migration compared to 
untreated controls whereas TEC-H8 migration was inhibited by ~ 40 % (Fig. 3A). TGFβ2 
also markedly enhanced TEC-H8 contraction in collagen gel contraction assays, while 
exerting little effect on NEC-B12 (unpublished data, DJK). These results are consistent with 
previous studies showing impaired migration of SMA+ myofibroblasts and are perhaps 
related to higher contractility and increased focal adhesions associated with filamentous 
actin stress fibers (29–31). In contrast, formation of in vitro vascular structures was inhibited 
by 60–80 % in NEC-B12 and SMA-low TEC (TEC-A2) challenged with TGFβ2 but were 
increased by 40 % in TEC-H8 (Fig. 3B). Taken together, our data suggest that 
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subpopulations of EC are differentially receptive to TGFβ stimulation: some are 
characterized by high SMA induction, decreased migration, and stabilized vascular 
structures whereas others respond oppositely.
TGFβ induces diverse genetic signatures in different types of EC
We next used qPCR to compare the expression pattern of 12 mesenchymal marker genes in 
TGFβ2-treated NEC-B12 versus TEC-H8 cultures. Strikingly, we found the pattern of gene 
expression to be entirely opposite when these genes were hierarchically clustered (Fig. 4A). 
For example, whereas NEC-B12 strongly up-regulated mesenchymal markers including 
calponin 1 (Cnn1), transgelin (Tagln), cadherin 11 (Cdh11), and endosialin (Cd248), TEC-
H8 strongly increased the expression of Acta2 (SMA), fibronectin 1 (Fn1), platelet-derived 
growth factor (PDGF) receptor β (Pdgfrβ), and desmin (Des). Basal FN1 protein expression 
was also slightly higher in TEC-H8 and was further increased after TGFβ2 stimulation as 
shown by Western blotting (Fig. S1A). Another cluster of mesenchymal genes including 
tenascin c (Tnc), endoglin (Eng), and vimentin (Vim) were slightly elevated in TEC-H8 and 
their levels were variably altered by TGFβ2 treatment. The EC markers Cdh5, Cd31, and 
Vegfr1 were either moderately decreased or unchanged by TGFβ2 challenge. Longer periods 
of TGFβ2 treatment could result in sustained down-regulation of these and other EC-specific 
genes. Notably, the pericyte marker Ng2 was not detected in NEC or TEC-H8 with or 
without TGFβ2 treatment, ruling out the presence of contaminating pericytes in these 
cultures (data not shown).
Because both SMAD-dependent and SMAD-independent pathways are implicated in 
mesenchymal gene regulation during EndMT, we used pharmacological inhibitors to 
evaluate different mechanisms of TGFβ2-induced SMA expression in TEC (32). We found 
that TGFβ regulated SMA expression in TEC via PI3K, Akt, and SMAD3, but not through 
mTOR (Fig. 4B). To determine whether differential expression of SMADs could account for 
the divergent responses to TGFβ2 in NEC versus TEC cultures, we assessed levels of 
pSMAD2 and pSMAD3 using Western blotting. We found similar basal pSMAD2 and 
pSMAD3 levels in both NEC-B12 and TEC-H8 cultures (Fig. S1B and S1C). TGFβ2 further 
induced SMAD2 and SMAD3 phosphorylation in the two cell types to a similar level, with 
comparable total SMAD2/3 expression, indicating that TGFβ2-signaling is not altered in 
TEC-H8 compared to NEC-B12. However, TGFβ2-activated SMADs regulate distinct 
groups of target genes in NEC versus TEC suggesting that either additional cofactors are 
differentially recruited to mesenchymal gene promoters in the two cell types or that a 
different set of mesenchymal genes may be poised for transcription in different types of EC.
Only a fraction of tumor vessels contain SMA+ endothelial cells in vivo
We found that primary EC clones displayed a spectrum of SMA expression upon TGFβ2 
stimulation suggesting that not all EC respond identically to TGFβ2 challenge. To test this 
possibility in vivo, we fate-mapped tumor endothelium using ZsGreenCdh5-Cre reporter mice 
to indelibly mark all EC (Fig. S2A and S2B). Three-dimensional confocal imaging of these 
tumors at high magnification clearly demonstrated that SMA and ZsGreen localized in the 
same cells (Fig. S2C, S3, and Movie S1). Consistent with our in vitro findings, we observed 
that in two different orthotopically implanted mammary tumors, only a minor fraction (~ 1–
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10 %) of tumor blood vessels contained SMA+ EC, whereas few if any SMA+ EC were 
found in normal mammary glands (Fig. 4C). On the other hand, blood vessels in 
spontaneous C3-TAg mammary tumors and K-RasG12D lung tumors showed a broad range 
(0–25 %) of CD31 and SMA co-expression in EC (Fig. 4D). The higher frequency of 
CD31+/SMA+ EC in these genetically engineered mouse (GEM) models could be due to the 
longer tumor growth period, or in the case of lung, be related to underlying plasticity 
inherent within the vascular bed (i.e. different vascular beds show differential proclivity to 
undergo EndMT). However, it is challenging to discriminate between SMA+ pericytes and 
the closely underlying CD31+ EC using immunostaining in these models and these results 
must be interpreted with caution; therefore the frequency of CD31+/SMA+ EC in these 
GEM models could be overestimated.
These results suggest that EC variably acquire SMA expression in the tumor models we 
evaluated, but SMA+ EC may be more common in other tumor types; for example, in 
pancreatic tumors where fibrosis is a prominent feature and the percentages reported are 
markedly higher (~ 40 %) (5). SMA+ EC might appear only transiently during different 
stages of tumor progression, or are generated continuously, but can revert to SMA− EC 
depending on the balance of EndMT promoting (or inhibiting) factors present in the tumor 
microenvironment. Though ZsGreenCdh5-Cre mice are a high-fidelity EC lineage tracing 
model, it is also conceptually possible that SMA+ fibroblasts or other mesenchymal-lineage 
cells may acquire EC markers through mesenchymal-endothelial transition (MEndT), which 
is a reverse process of EndMT. While EndMT has been observed in a wide range of 
conditions, the phenomenon of MEndT in tumors is still a matter of debate (33). In contrast 
to EndMT which may arise spontaneously in vitro, generation of EC from lineage-
committed mesenchymal cells requires enforced induction of multiple EC-selective 
transcription factors in addition to TGFβ inhibition, indicating that MEndT demands 
restrictive conditions and precise temporal activation of specific regulatory factors (34). 
Therefore, SMA+ EC in our model are more likely to be originated from endothelial-lineage 
cells via EndMT rather than mesenchymal-lineage cells through MEndT.
bFGF opposes the expression of some TGFβ target genes but augments the expression of 
others
Similar to epithelial-to-mesenchymal transition (EMT), we expected that conversion of EC 
to mesenchymal-like cells was dynamic and could be reversed upon removal of TGFβ2 from 
the culture medium. Indeed, we found that when TGFβ2 was removed and cells were 
returned to their normal growth medium which contains bFGF (EC media), SMA expression 
was rapidly lost and TEC regained their typical EC morphology (Fig. S4A and S4B). The 
same cell population up-regulated SMA again after being returned to TGFβ2-containing 
media, indicating that some TEC may readily morph between SMA− endothelial and SMA+ 
mesenchymal-like phenotypes. We further determined that bFGF, but not VEGF, suppressed 
TGFβ2-induced SMA expression (Fig. 5A). Similar to interstitial cells in the heart, bFGF 
neutralized TGFβ2-stimulated SMA expression in TEC at 500 pg/mL, a concentration that 
was 20-fold lower than the TGFβ2 concentration added to the culture medium (Fig. 5B) 
(35). Remarkably, acidic FGF (aFGF), the closely related isoform of bFGF, did not 
neutralize SMA expression in TGFβ2-challenged cells at the same concentrations. 
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Suppression of TGFβ2-induced SMA expression by bFGF was confirmed at the protein 
level by immunofluorescence (Fig. 5C). Simply removing bFGF from the culture medium 
promoted TEC to drift towards a mesenchymal-like phenotype indicated by a moderate 
increase in SMA expression, especially in cells maintained at subconfluent conditions (Fig. 
S4C). Moreover, these subconfluent cells were highly receptive to TGFβ stimulation 
compared to confluent cultures and showed robust SMA induction and more pronounced 
VEGFR2 suppression (Fig. S4C), indicating that loss of cell–cell contact enhances TGFβ 
responses. Thus, bFGF functions both as a potent EC mitogen and a “specification factor” 
that prevents EC drift towards mesenchymal-like cell types, particularly in the presence of 
TGFβ.
Next, we carried out a TGFβ2 pathway qPCR array to comprehensively assess the 
expression of 84 TGFβ2 target genes in NEC versus TEC cultures, either with or without 
addition of bFGF. The results showed that, as predicted, TGFβ2 induced distinct expression 
patterns in NEC versus TEC cultures (Fig. 5D). Furthermore, while bFGF counteracts 
TGFβ2-induced expression of the mesenchymal genes Acta2 and thrombospondin 1 (Thbs1), 
TGFβ2 and bFGF synergistically activate other genes such as Notch1 and S100a8, which 
were shown previously to regulate tumor angiogenesis (Fig. 5D) (36,37). While repressing 
SMA, bFGF rescued the expression of Vegfr-2, which is suppressed by TGFβ2 challenge; 
however, bFGF only marginally down-regulated expression of the transcription factor Snail, 
which was previously identified as a master regulator of EndMT (Fig. S4D) (38). 
Interestingly, bFGF expression was increased by TGFβ2 stimulation, suggesting a possible 
autocrine or paracrine feedback loop in EC to counteract TGFβ2-induced expression of 
specific target genes, namely SMA (Fig. S4D).
To further confirm the protective role of bFGF in neutralizing TGFβ-induced SMA 
expression, we examined gene expression patterns in an additional C3-TAg TEC clone with 
relatively low basal SMA mRNA (TEC-G8). bFGF completely suppressed TGFβ-induced 
SMA expression in TEC-G8, even though the SMA levels were significantly lower than 
those in the SMA+ clone TEC-H8 (Fig. S5A and S5B). To assess the interaction between 
bFGF and TGFβ in EC derived from a different tumor model, we isolated lung TEC from K-
RasG12D mouse lung tumors (22). All clones were virtually 100 % positive for DiI-Ac-
LDL uptake and CD31, and strongly expressed VEGFR2 (Fig. S6A and S6B). Interestingly, 
unlike C3-TAg TEC clones, the K-Ras TEC clones showed elevated basal SMA protein that 
was detectable by Western blotting even in EC media that contained bFGF, suggestive of a 
“partial” EndMT phenotype in EC subpopulations derived from lung. The expression of 
SMA and other myofibroblast markers including Col1a1, Fn1, and Tagln in these K-Ras 
clones was further stimulated by TGFβ2 in the absence of bFGF, although to a lesser extent 
when compared to SMA+ mammary TEC (Fig. S6B and S6C). Addition of bFGF variably 
antagonized the effect of TGFβ on these genes, indicating that bFGF may act through 
similar pathways in different types of EC to maintain EC fate (Fig. S6C). Although Twist1 
and Twist2 have been implicated in the induction of mesenchymal genes during EndMT and 
EMT; surprisingly, we did not observe an up-regulation of Twist1 or Twist2 by TGFβ (39). 
It is possible that induction of these genes in EC requires prolonged stimulation with TGFβ 
or they play only a marginal role during EndMT.
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Previous studies have demonstrated that bFGF can antagonize TGFβ through the 
MAPK/ERK kinase pathway to suppress fibrogenic effects in epithelial cells and revert 
EMT, a process closely related to EndMT (40). Providing a further link between bFGF and 
TGFβ signaling, basal SMAD2 phosphorylation and TGFβR1 levels are increased when 
FRS2, an FGFR co-activator, is depleted using shRNA (41). In lymphatic EC, bFGF was 
reported to suppress TGFβ-stimulated SMAD2 activation via MAPK signaling (42). 
However, we found that although bFGF strongly induced EKR1/2 activation, it exerted no 
observable effects on TGFβ2-stimulated SMAD2 phosphorylation and only weakly reduced 
SMAD3 phosphorylation after a 60-minute TGFβ2 stimulation (Fig. S7A). Furthermore, 
inhibition of MAPK/ERK only mildly disabled the opposing effect of bFGF on TGFβ-
induced SMA (Fig. S7B), indicating that bFGF may counteract TGFβ signaling through 
additional mechanisms.
Bone morphogenetic proteins (BMPs), which are members of the TGFβ superfamily, can 
interact synergistically or antagonistically with TGFβ to fine-tune cellular differentiation. 
For example, BMP-2 controls cardiac valve formation through Snail1-mediated EMT during 
heart development, while BMP-7 was reported to attenuate TGFβ-induced EndMT in 
cardiac fibrosis (4,43). In addition, BMP-6 acts as a major inhibitor of renal fibrosis as loss 
of BMP-6 increases SMA and FN1 expression in obstructed kidneys (44). However, we 
found that treatment with BMP-2, 6, or 7 did not overly affect SMA or FN1 expression 
stimulated by TGFβ2 in EC (Fig. S7C), suggesting that interaction between TGFβ and BMP 
signaling may be cell-type dependent. More specifically, different types of EC may respond 
differently to combinations of TGFβ and BMP signals. Taken together, our results suggest 
that EndMT, while sharing many features with EMT, is a distinctly regulated process that is 
variably regulated in different vascular beds, or in different disease settings.
EC challenged with TGFβ secrete their own bFGF which suppresses mesenchymal-like 
differentiation in secondary cultures
Because bFGF potently blocks TGFβ-stimulated conversion to SMA+ mesenchymal cells, 
and EC up-regulate bFGF in response to TGFβ, we asked whether a cell autonomous 
mechanism in EC could counteract TGFβ challenge. Consistent with our findings, a recent 
study using microarrays also showed that EC challenged with TGFβ up-regulate bFGF 
mRNA (2). First, we confirmed that TGFβ2 dose-dependently increased bFGF mRNA 
expression, with a maximum ~ 10-fold increase after 10 ng/mL TGFβ2 treatment (Fig. 6A). 
TGFβ2 also time-dependently increased bFGF expression, with maximum levels peaking at 
~ 10-fold above untreated control cells after 48 hours. Next, we harvested the conditioned 
medium (CM) and cellular lysates of TGFβ2-challenged TEC. We found a striking time-
dependent increase in bFGF secretion and a slight increase in bFGF expression in the 
cellular lysates after TGFβ2 stimulation (Fig. 6B). Notably, we observed that secreted bFGF 
migrated at three different molecular weights, which is consistent with a previous study 
reporting multiple splice variants of bFGF (45).
To determine whether EC-derived bFGF could oppose TGFβ2 activity, we challenged TEC 
cultures with TGFβ2 and then harvested the CM to re-challenge secondary cultures (Fig. 6C, 
a). We found that CM collected from TEC stimulated with TGFβ2 induced ~ two-fold less 
Xiao et al. Page 10













SMA expression in secondary cultures treated with cell-free media containing equal 
amounts of TGFβ2 (Fig. 6C, b–c). The decrease in SMA expression in secondary cultures 
correlated with the presence of secreted bFGF protein in the CM. qPCR analysis of 
additional mesenchymal and EC genes, including Tagln, Pdgfa, Thbsp1, Cd31, and Cdh5, 
further showed that the CM of TGFβ2-challenged primary cultures could oppose the effects 
of TGFβ2 in secondary cultures. In contrast, S1008a, which can be induced synergistically 
by TGFβ2 and bFGF as revealed by the TGFβ-pathway array (refer to Fig. 5D), showed a 
similar expression pattern after the CM treatment, while the expression of Snail was not 
affected. To test if the TGFβ2-antagonizing effect of the CM was due specifically to an 
increased bFGF production by TEC, we used a bFGF blocking antibody (BA) and an FGFR 
kinase inhibitor (KI) to neutralize bFGF activity. As expected, blocking bFGF signaling by 
either compound increased TGFβ2-stimulated SMA mRNA expression in TEC (Fig. 6C, d). 
However, neutralizing bFGF with a BA or KI only had a modest effect on SMA expression, 
possibly because SMA mRNA levels were already maximized by the addition of TGFβ2.
Our results have shown that EC exhibit heterogeneity in their responses to TGFβ: some 
express high basal SMA and react to TGFβ by generating SMA+ myofibroblast-like cells 
with distinct functions, whereas others have low basal SMA and transition to SMA− 
fibroblast-like cells (Fig. 7). These results are remarkably similar to what has been reported 
for epithelial cells and suggests parallels between the processes of EMT and EndMT (46). 
However, EC which have undergone a partial mesenchymal-like transition may be directed 
to a stable SMA+ mesenchymal-like phenotype perhaps after prolonged TGFβ stimulation or 
disruption in bFGF signaling (41). In addition to regulation by growth factors and cytokines, 
EndMT may also be controlled by epigenetic barriers within the different subpopulations of 
EC that guides them towards one lineage or the other. These epigenetic restrictions could 
explain heterogeneity in EC responses to TGFβ signaling. EC markedly increase bFGF 
production in response to stimulation by TGFβ2; thus, one EC that receives TGFβ could 
protect neighboring EC from mesenchymal-like differentiation through a lateral inhibitory 
mechanism involving bFGF secretion (47). A similar mechanism of lateral inhibition 
involving VEGF/Notch signaling is well known in EC, as it occurs during fate determination 
of tip cells during sprouting angiogenesis (48). In tumors, organ fibrosis, and other chronic 
inflammatory conditions, the extent of EndMT will likely be determined by local 
concentrations of several interacting cytokines and growth factors, including TGFβ, bFGF, 
and BMPs, and perhaps on organ-specific properties and heterogeneity of the EC that form 
the microvasculature (49). Notably, in endoglin- (a TGFβ2 co-receptor) deficient mice, 
EndMT in tumor vessels was exacerbated and the frequency of metastases was increased 
(13). On the other hand, endoglin deficiency delayed resistance to an anti-angiogenic 
therapy targeting VEGF. These findings bring to light the importance of further 
understanding the molecular mechanisms that promote and inhibit EndMT in tumors and in 
other pathological conditions.
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Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Isolation and characterization of NEC and TEC clones
(A) Schematic diagram of EC isolation procedure. (B) Representative CD31 and CDH5 
FACS histogram plots of NEC and TEC clones. Open curves represent cells stained with 
CD31 or CDH5 antibodies, and solid curves indicate FACS histogram plots of cells stained 
with an isotype-matched control antibody. (C) Relative mRNA expression by qPCR of 
Acta2 (SMA), Cd31, and Vegfr-2 in NEC and TEC clones. Gapdh was used as an 
endogenous control and relative mRNA expression of each gene was expressed as fold 
increase compared to NEC. MSC were used as a positive control.
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Figure 2. Subpopulations of EC undergo a spectrum of EndMT in response to TGFβ2 
stimulation
(A) Western blots showing that TGFβ increases SMA protein expression in TEC-H8, a clone 
that has high basal SMA mRNA levels. Three clones representing NEC (NEC-B12), SMA-
low TEC (TEC-A2), and SMA-high TEC (TEC-H8) were treated with 10 ng/mL TGFβ2 in 
growth factor (GF)-reduced media (20 % FBS LG-DMEM) for 48 hours before being 
subjected to Western blotting. MSC were used as a positive control. (B) Western blots 
showing SMA expression in NEC-B12 and TEC-H8 after stimulation with 10 ng/mL 
TGFβ1, TGFβ2, or TGFβ3 for 48 hours. (C) Western blots showing SMA expression in 
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TEC-D8 and prostate TEC isolated from TRAMP mice after stimulation with 10 ng/mL 
TGFβ2 for 48 hours. (D) Immunofluorescence images of TEC-H8 stimulated with 10 ng/mL 
TGFβ2 for 48 hours. Cells were stained with SMA (red, a), CD31 (green, b), and DAPI 
(blue) as shown in the merged image (c). (d) Merged confocal image of TGFβ2-stimulated 
TEC-H8. The white arrowheads indicate co-localization of SMA (red) and CD31 (green) in 
the same cell. Scale bars = 50 μm.
Xiao et al. Page 17














(A) (a) Wound closure rates of NEC-B12 and TEC-H8 treated with or without TGFβ2. (b) 
Representative images of the wound closure at indicated time points. White dotted lines 
indicate the migration fronts of cells. Cells were exposed to 10 ng/mL TGFβ2 in 20 % FBS 
LG-DMEM for ~ 30 minutes before imaging (n = 3). Scale bar = 100 μm. Statistical 
significance was determined by two-way ANOVA (**P < 0.001). (B) Representative phase-
contrast images of Matrigel tube formation of NEC (a, b), TEC-G8 (c, d), and TEC-H8 (e, f) 
with or without TGFβ2 treatment. (g) Quantification of tubes by counting the number of 
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tubes per field. Scale bar = 1 mm. n = 3–4 observations. Statistical significance was 
determined using a Student’s t test (*P < 0.05).
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Figure 4. Only a fraction of tumor vessels contain SMA+ TEC
(A) Heat-map representation of mesenchymal and endothelial marker mRNA levels by 
qPCR in NEC-B12 and TEC-H8 clones treated with or without of TGFβ2. Gapdh was used 
as an endogenous control. The heat map was generated using Gene-E software. (B) Western 
blots demonstrating that TGFβ2 up-regulates SMA expression in TEC-H8 via SMAD2/3 
and PI3K pathways. TGFβ2R inhibitor (SB431542): 10 μM, PI3K inhibitor (LY294002): 3 
μM, Akt inhibitor VIII: 5 μM, SMAD 3 inhibitor (SIS3): 3 μM, and mTOR inhibitor 
(rapamycin): 100 nM. (C) Representative immunofluorescent images of normal mammary 
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glands (Normal MG) (a–c) and mammary tumors (d–f) from lineage-traced ZsGreenCdh5-cre 
mice showing SMA staining (red), blood vessels that are tagged with ZsGreen (green), and 
nuclear staining with DAPI (blue). Mammary tumors were induced by orthotopic injection 
of E0771 or PyVMT tumor cells in ZsGreenCdh5-cre mice. The arrowheads indicate 
ZsGreen+/SMA+ vessels and asterisks indicate ZsGreen+/SMA− vessels. (g) Quantification 
of vessels containing ZsGreen+/SMA+ cells in normal mammary glands and mammary 
tumors. (D) Representative immunofluorescent staining of SMA (red), CD31 (green), and 
DAPI (blue) in spontaneous C3-TAg mammary tumors (a–c) and K-RasG12D lung tumors 
(d–f). The arrowheads indicate ZsGreen+/SMA+ vessels. Scale bars = 100 μm. (g) 
Frequency distribution of vessels containing CD31+/SMA+ cells in C3-TAg and K-
RasG12D tumors. Each bar represents one microscopic field of view.
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Figure 5. bFGF opposes the expression of some TGFβ target genes but augments the expression 
of others
(A) Western blots showing that bFGF but not VEGF blocks SMA protein expression in 
TEC-H8. (B) (a) Representative Western blots demonstrating that bFGF suppresses TGFβ2-
induced SMA expression in a dose-dependent manner. (b) Densitometry quantification of 
SMA expression (n = 3). Statistical significance was determined using One-way ANOVA 
with Bonferroni post test (**P < 0.01). ADU: arbitrary density units. (c) Western blots 
showing that aFGF does not suppress TGFβ2-induced SMA expression. (C) Representative 
immunofluorescent images of SMA expression in TEC-H8 stimulated with TGFβ2 in the 
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absence (a) or presence (b) of bFGF. (c) Quantification of SMA+ cells from 
immunofluorescence. Scale bar = 100 μm. (D) Heat map and hierarchical clustering of gene 
expression of NEC and TEC-H8 clones analyzed using the Mouse TGFβ Signaling Targets 
RT2 Profiler™ PCR Array. Cells were stimulated for 48 hours with TGFβ2 and/or bFGF as 
indicated, and the arrays were performed in duplicate. Results were normalized and log-
transformed, and genes were clustered using Pearson’s correlation.
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Figure 6. EC challenged with TGFβ secrete their own bFGF which suppresses mesenchymal-like 
differentiation in secondary cultures
(A) Dose- and time-dependent induction of bFGF mRNA expression in TEC-H8 challenged 
with TGFβ2. In the dose-response experiment, cells were treated with increasing 
concentrations of TGFβ2 for 48 hours, and in the time-dependent experiment, cells were 
stimulated with 10 ng/mL TGFβ2. (B) Western blots showing secreted and intracellular 
bFGF in TEC-H8 challenged with 10 ng/mL TGFβ2 for the indicated times. Ponceau 
staining (PS) and GAPDH were used as loading controls for secreted proteins and cell 
lysates, respectively. The arrowheads indicate bFGF isoforms of different molecular 
weights. (C) Secondary TEC-H8 culture treatments with conditioned media (CM) obtained 
from TEC-H8 challenged with TGFβ2. (a) Schematic diagram of the CM experiment. Media 
conditioned by TEC-H8 stimulated with or without TGFβ2, and media containing only 
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TGFβ2 were concentrated and used to treat secondary TEC-H8 cultures for 48 hours. (b) 
Western blot of SMA expression in the secondary TEC cultures treated with CM or cell-free 
media, and Western analysis of secreted bFGF in the CM and cell-free media. (c) qPCR 
analysis of changes in mRNA expression in secondary TEC-H8 cultures treated with CM or 
cell-free media. (d) qPCR analysis of Acta2 (SMA) mRNA expression in TEC-H8 treated 
with increasing doses of either a bFGF blocking antibody (BA) or a FGFR kinase inhibitor 
(KI) in the presence of 10 ng/mL TGFβ2 for 48 hours. From left to right: the bFGF BA 
concentrations are 0 μg/mL, 20 μg/mL, 0 μg/mL, 10 μg/mL, 15 μg/mL, and 20 μg/mL, and 
the FGFR KI concentrations are 0 nM, 200 nM, 0 nM, 40 nM, 120 nM, and 200 nM. Graphs 
are representative of three independent experiments. Error bars represent SEM (n = 3). 
Significance was determined using a one-way ANOVA and is indicated by an asterisk (P < 
0.05).
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Figure 7. Schematic diagram of TGFβ and bFGF interactions during EndMT
Heterogeneous EC populations consist of cells with a spectrum of basal SMA mRNA 
expression suggesting that some EC possess intrinsic ability to gain SMA protein 
expression. Transient TGFβ exposure stimulates EC to undergo reversible EndMT where 
some EC transition into SMA+ intermediate cells whereas others form SMA− intermediate 
cells. EC also up-regulate bFGF in response to TGFβ, providing a mechanism to counteract 
TGFβ, thereby maintaining endothelial specification via an autocrine or paracrine loop. 
Prolonged TGFβ stimulation may force EC to reach a “point of no return” and enter an 
irreversible or stable EndMT state. EC at this stage may completely lose endothelial 
specification, which cannot be rescued by bFGF addition or TGFβ removal, and generate 
either SMA+ or SMA− mesenchymal-like cells. It is also possible there are epigenetic 
barriers are in place among heterogeneous EC that restricts SMA− mesenchymal-like EC 
from becoming SMA+, but these barriers could be overcome depending on specific 
conditions in the tumor microenvironment.
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